Navigation Links
Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
Date:5/21/2008

LAWRENCEVILLE, N.J., May 21 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a marketing and distribution agreement with PharmaLink Asia Pacific Pte. Ltd. to enable Aton to expand distribution into several countries in Asia and Australia.

"This partnership marks an important milestone for Aton as we execute our mission to expand access to our medically essential portfolio of products," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "PharmaLink is uniquely qualified to help us expand our reach into the Asia Pacific region."

"Aton has a portfolio of unique products, and we are excited to partner with them to serve patients who rely on the availability of these medicines," stated Dr. George Eassey, VP of PharmaLink Asia Pacific. "We look forward to a long and successful partnership with Aton."

PharmaLink is a subsidiary of the INVIDA group and a leading provider of pharmaceutical and healthcare marketing and sales services in the Asia Pacific region. PharmaLink's strong presence, with subsidiaries across Asia Pacific and associates representing 13 countries within the region, as well as the company's in-depth understanding of these markets, enables PharmaLink to enhance the potential of clients' brands and products.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

About Invida Pharmaceutical Holdings Pte. Ltd.

Invida Pharmaceutical Holdings Pte. Ltd. is a specialty pharmaceutical company and the parent of PharmaLink, which is the leading pharmaceutical and healthcare commercialization services provider in Asia Pacific; and Inovail, an independently-managed, specialty pharmaceutical company focused on market-driven innovation in the areas of dermatology, complementary oncology and female healthcare. Headquartered in Singapore, Invida's focus is in the Asia Pacific region, where it has offices in 13 countries. Its shareholders include Temasek Holdings, Quintiles Transnational and the Zuellig Group. More information about Invida can be found at http://www.invida.com.


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
2. Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
3. TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech
4. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
5. Pharmaxis Aridol Authorised for Sale in Germany
6. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
7. China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R)
11. Transdel Pharmaceuticals Closes $4 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
Breaking Biology Technology:
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
Breaking Biology News(10 mins):